What is BioStable Science & Engineering?
BioStable Science & Engineering operates at the intersection of cardiovascular surgery and medical device innovation. The company is primarily recognized for its HAART Aortic Repair Technologies, a suite of proprietary solutions designed to offer a viable alternative to traditional valve replacement. By focusing on simplifying and standardizing the surgical repair process, BioStable enables clinicians to provide patients with the clinical benefits of repair over replacement, particularly for those suffering from aortic insufficiency or aortic aneurysms. The company's market position is defined by its commitment to improving patient outcomes through less invasive, highly standardized surgical techniques that preserve natural anatomy.
How much funding has BioStable Science & Engineering raised?
BioStable Science & Engineering has raised a total of $14M across 3 funding rounds:
Series A
$5.5M
Series B
$4.3M
Series C
$4.2M
Series A (2008): $5.5M with participation from Sante Ventures
Series B (2015): $4.3M led by Sante Ventures
Series C (2020): $4.2M supported by Orlando Health Ventures and Rex Health Ventures
Key Investors in BioStable Science & Engineering
Sante Ventures
A specialized investment firm focused on healthcare and technology, managing over $1 billion in capital with a deep emphasis on Biotech, Medtech, and Healthtech sectors.
Rex Health Ventures
The investment arm of UNC REX Healthcare, a private, not-for-profit health care system dedicated to supporting innovative medical advancements.
Orlando Health Ventures
A strategic investment entity associated with a major health system, focusing on fostering innovation in clinical care and medical technology.
What's next for BioStable Science & Engineering?
With the recent infusion of capital, BioStable Science & Engineering is poised to accelerate the commercialization and adoption of its HAART platform. The strategic focus will likely shift toward expanding clinical evidence, broadening surgeon training programs, and navigating the regulatory landscape to increase market penetration. As the company matures, the emphasis will remain on demonstrating the long-term durability and efficacy of its repair technologies compared to standard replacement valves. This phase of growth is critical for establishing the company as a standard-bearer in the cardiovascular space, potentially setting the stage for further market expansion or strategic partnerships within the broader medical technology ecosystem.
See full BioStable Science & Engineering company page
